Clinical Trial Update: Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) [Phase 2]

View source ↗

Summary

Phase 2 trial update on Uprifosbuvir with Ruzasvir in chronic hepatitis C showing terminated status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ruzasvir (ruzasvir)
• Uprifosbuvir (uprifosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2018-08-06